Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 December 2022Website:
http://www.coyatherapeutics.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 18:44:35 GMTDividend
Analysts recommendations
Institutional Ownership
COYA Latest News
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives. The development and production of exosomes from patients' regulatory T cells will be funded by the Johnson.
Coya Therapeutics (COYA) is a clinical-stage company focused on developing multi-modality Treg therapies. CEO Howard Berman joins Nicole Petallides to give an overview of the company.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the completion of a randomized, double-blind, placebo-controlled Phase 2 study of LD IL-2 in patients with mild-to-moderate AD. The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheim.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the Alzheimer's Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company's common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million. The ADDF's mission is to rapidly accelerate the development of drugs to prevent, trea.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Deve.
Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could potentially be the best drug on the market, halting ALS disease progression. Coya's shares appear undervalued based on simplified valuation methods (risk-adjusted, discounted peak sales multiple).
Shares of Coya Therapeutics Inc. COYA, +3.33% gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a study of its investigational therapy COYA 301 in patients with mild to moderate Alzheimer's disease. An open-label study in eight patients found a decrease in neuroinflammation following treatment with the therapy, the company said in a release.
Recently, IPO'd Coya has just reported cognition-improving and cognition-stabilizing results in an open label study in Alzheimer's patients with Coya 301. In March 2023, Coya had reported stabilization of ALS patients over 24 weeks and minimal decline over 48 weeks with Coya 302.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Coya Therapeutics, Inc. (COYA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced management will present at the Virtual Investor Summit on Wednesday, March 29, 2023 at 11:00am ET. Investors can view the webcast here. Management will be available for one-on-one meetings at the conference.
What type of business is Coya Therapeutics?
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
What sector is Coya Therapeutics in?
Coya Therapeutics is in the Healthcare sector
What industry is Coya Therapeutics in?
Coya Therapeutics is in the Biotechnology industry
What country is Coya Therapeutics from?
Coya Therapeutics is headquartered in United States
When did Coya Therapeutics go public?
Coya Therapeutics initial public offering (IPO) was on 29 December 2022
What is Coya Therapeutics website?
https://www.coyatherapeutics.com
Is Coya Therapeutics in the S&P 500?
No, Coya Therapeutics is not included in the S&P 500 index
Is Coya Therapeutics in the NASDAQ 100?
No, Coya Therapeutics is not included in the NASDAQ 100 index
Is Coya Therapeutics in the Dow Jones?
No, Coya Therapeutics is not included in the Dow Jones index
When does Coya Therapeutics report earnings?
The next expected earnings date for Coya Therapeutics is 08 August 2024